Protalix reports Q3 2026 results, reaffirms revenue guidance, RELEASE gout study enrollingNov 10Quarterly updateProtalix BioTherapeutics, Inc.
Gossamer Bio submits first NDA, for seralutinib in PAH, to FDANov 10Quarterly updateGossamer Bio, Inc.seralutinib